The DOI matches its Crossref record; 60 of the 63 references it cites were found in a registry or an index.
Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment
Open accessAbstract
Adeno-associated virus (AAV)-based vectors expressing therapeutic genes continue to demonstrate great promise for the treatment of a wide variety of diseases and together with other gene transfer vectors represent an emerging new therapeutic paradigm comparable in potential impact on human health to that achieved by recombinant proteins and vaccines. A challenge for the current pipeline of AAV-based investigational products as they advance through clinical development is the identification, characterization and lot-to-lot control of the process- and product-related impurities present in even highly purified preparations. Especially challenging are AAV vector product-related impurities that closely resemble the vector itself and are, in some cases, without clear precedent in established biotherapeutic products. The determination of acceptable levels of these impurities in vectors prepared for human clinical product development, with the goal of new product licensure, requires careful risk and feasibility assessment. This review focuses primarily on the AAV product-related impurities that have been described in vectors prepared for clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ratio of full capsids to all capsids, termed content ratio, can vary from <1% to 30% in the production culture at the time of harvest and is inconsistent between production runs (Figure 1).6,28, 29, 30”
From Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies (2021) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike empty capsids, partially filled capsids and full capsids with host cell/plasmid DNA may have additional genotoxic effects, depending on the type of encapsidated genome.28”
From Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies (2021) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Empty capsids, as well as capsids with non-transgene sequences, can elicit an unnecessary immune response and compete for vector binding sites, increasing the risk of immunotoxicity and lowering the rate of transduction of full capsids, which are required for product efficacy.28,30”
From Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies (2021) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aggregates of capsids, as the third potential CQA, represent another product-related impurity with detrimental impact on safety and long-term stability of the vector product, as even trace amounts (e.g., <1%) provide nucleation sites for further aggregation.28,44,45”
From Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies (2021) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the periphery, AAV-mediated gene delivery can elicit humoral, cellular, and innate immune responses to features including the viral capsid, expressed transgene, and impurities from the viral preparation,6,7”
From An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission (2024) · cites this paper as [7]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 2×
“A cluster of differentiation (CD) 8 T-cell response directed against AAV capsid was implicated in the recognition and clearance of transduced hepatocytes in clinical trials using AAV2-hFIX [35,36] and AAV8-hFIX [11], and peptides derived from empty capsids themselves have been demonstrated to gain access to MHC Class…”
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“For example, in trials for LCA2, AAV-mediated delivery by sub-retinal injection of less than one microgram of DNA encoding retinal pigment epithelium-associated 65 kDa protein (RPE65) retinal isomerase achieved significant improvements in visual function for more than three years (and counting) [4–10].”
MethodSelf-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“For example, in trials for LCA2, AAV-mediated delivery by sub-retinal injection of less than one microgram of DNA encoding retinal pigment epithelium-associated 65 kDa protein (RPE65) retinal isomerase achieved significant improvements in visual function for more than three years (and counting) [4–10].”
MethodAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 2×
“For example, AAV vector production systems based on human cell lines [21–24] and insect cell lines [25–27] result in qualitative differences in the nature of residual host cell proteins and nucleic acids, with corresponding differences in the risk of potential immunotoxicity”
BackgroundZolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312 · cited 2×
“For AAV2 vectors, P:I ratios in the range of 5–1000 have been reported with permissive cell culture systems using adenovirus to provide helper virus functions [42,63,64].”
MethodBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 1×
“Infection by wild-type AAV Type 2 is common in the human population [58], with no known associated pathology.”
BackgroundHauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954 · cited 1×
“For example, in trials for LCA2, AAV-mediated delivery by sub-retinal injection of less than one microgram of DNA encoding retinal pigment epithelium-associated 65 kDa protein (RPE65) retinal isomerase achieved significant improvements in visual function for more than three years (and counting) [4–10].”
MethodTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Research works printed but not linked: 2
- Belter, P.A., Cussler, C.L., and Hu, W.S. (1988). Bioseparations, John Wiley and Sons.
- Sadana, A. (1998). Bioseparation of Proteins, Academic Press.
Cited by
Progress and challenges in viral vector manufacturing
van der Loo, J. C. M., & Wright, J. F. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv451 · Cited by 255
“Viral vector-encapsidated nucleic acid impuritiesmay include fragments from any available source of DNA in the production milieu, including DNA from helper components (plasmid or bacmid DNA) and from producer cells [reviewed in (121)].”
BackgroundSelf-citationManufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269
Pharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213
“serum- or other animal-derived products in the cell culture media, nucleic acids from host cells, and, in the case of AAV, non-transfected plasmid (90).”
BackgroundInfluentialGimpel, A. L., Katsikis, G., Sha, S., Maloney, A. J., Hong, M. S., Nguyen, T. N. T., Wolfrum, J., Springs, S. L., Sinskey, A. J., Manalis, S. R., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.010 · Cited by 185
“Differences among infectious, genome, and capsid titers of a rAAV sample Common ranges for the titers during the production process are given in their commonly used units and based on literature reporting rAAV production on large scales.(6,7,18,19,24,25,28,30,34) Table 2.”
BackgroundMethodInfluentialPharmacology of Recombinant Adeno-associated Virus Production
Penaud-Budloo, M., François, A., Clément, N., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.002 · Cited by 177
“Finally, specifications are not always established for rAAV quality tests, and the determination of acceptable levels of these impurities has to be done based on risk assessment studies.(58)”
Background
Metadata
- Authors
- Wright, J.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Wright, J.
- ORCID
- Wright, J.
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2014-03-03
- Volume
- 2
- Issue
- 1
- Pages
- 80-97
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC5423478
- OpenAlex
- W2112570403
- Cited by
- 219
- References
- 63
- Citations by year
- 2026: 32 · 2025: 40 · 2024: 27 · 2023: 39 · 2022: 22 · 2021: 29 · 2020: 8 · 2019: 10 · 2018: 4 · 2017: 6 · 2016: 1 · 2015: 1
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus vectors, recombinant AAV vectors, product-related impurities, process-related impurities, risk assessment, gene therapy, clinical development, impurity characterization, regulatory acceptance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment. https://app.cochat.ai/papers/10.3390/biomedicines2010080
- The paper
- Wright, J. (2014). Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment. Biomedicines. https://doi.org/10.3390/biomedicines2010080
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
